Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

키워드

참고문헌 (217)

1. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
2. Browning JD, "Molecular mediators of hepatic steatosis and liver injury", J Clin Invest, 114, pp.147~152 (2004)
3. Lemoinne S, "New and emerging anti-fibrotic therapeutics entering or already in clinical trials in chronic liver diseases", Curr Opin Pharmacol, 49, pp.60~70 (2019)
4. Westerbacka J, "Dietary fat content modifies liver fat in overweight nondiabetic subjects", J Clin Endocrinol Metab, 90, pp.2804~2809 (2005)
5. van der Meer RW, "Effects of short-term high-fat, high-energy diet on hepatic and myocardial triglyceride content in healthy men", J Clin Endocrinol Metab, 93, pp.2702~2708 (2008)
6. Lindeboom L, "Proton magnetic resonance spectroscopy reveals increased hepatic lipid content after a single high-fat meal with no additional modulation by added protein", Am J Clin Nutr, 101, pp.65~71 (2015)
7. Hernández EA, "Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance", J Clin Invest, 127, pp.695~708 (2017)
8. Kaikkonen JE, "Metabolic profiling of fatty liver in young and middle-aged adults : cross-sectional and prospective analyses of the young finns study", Hepatology, 65, pp.491~500 (2017)
9. Rosqvist F, "Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat : a randomized trial", J Clini Endocrinol Metab, 104, pp.6207~6219 (2019)
10. Puri P, "A lipidomic analysis of nonalcoholic fatty liver disease", Hepatology, 46, pp.1081~1090 (2007)
11. Gerber L, "Non-alcoholic fatty liver disease(NAFLD)is associated with low level of physical activity : a populationbased study", Aliment Pharmacol Ther, 36, pp.772~781 (2012)
12. Ryu S, "Relationship of sitting time and physical activity with non-alcoholic fatty liver disease", J Hepatology, 63, pp.1229~1237 (2015)
13. Marchesini G, "Nonalcoholic fatty liver disease : a feature of the metabolic syndrome", Diabetes, 50, pp.1844~1850 (2001)
14. Bugianesi E, "Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease : sites and mechanisms", Diabetologia, 48, pp.634~642 (2005)
15. Donnelly KL, "Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease", J Clin Invest, 115, pp.1343~1351 (2005)
16. Utzschneider KM, "Review : the role of insulin resistance in nonalcoholic fatty liver disease", J Clin Endocrinol Metab, 91, pp.4753~4761 (2006)
17. Shimano H, "Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells", J Clin Invest, 99, pp.846~854 (1997)
18. Tamura S, "Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease", J Clin Invest, 115, pp.1139~1142 (2005)
19. Wolfrum C, "Foxa2regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes", Nature, 432, pp.1027~1032 (2004)
20. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
21. Speliotes EK, "Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits", PLoS Genet, 7, pp.e1001324~ (2011)
22. Chambers JC, "Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma", Nat Genet, 43, pp.1131~1138 (2011)
23. Beer NL, "The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver", Hum Mol Genet, 18, pp.4081~4088 (2009)
24. Kozlitina J, "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 46, pp.352~356 (2014)
25. Mahdessian H, "TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content", Proc Natl Acad Sci U S A, 111, pp.8913~8918 (2014)
26. Lin YC, "Variants in the autophagy-related gene IRGM confer susceptibility to non-alcoholic fatty liver disease by modulating lipophagy", J Hepatol, 65, pp.1209~1216 (2016)
27. Bellini G, "The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children", J Hepatol, 67, pp.653~655 (2017)
28. Luukkonen PK, "Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of nonalcoholic fatty liver disease", J Hepatol, 76, pp.526~535 (2022)
29. Ma J, "A peripheral blood DNA methylation signature of hepatic fat reveals a potential causal pathway for nonalcoholic fatty liver disease", Diabetes, 68, pp.1073~1083 (2019)
30. Pirola CJ, "Circulating microRNA signature in non-alcoholic fatty liver disease : from serum non-coding RNAs to liver histology and disease pathogenesis", Gut, 64, pp.800~812 (2015)
31. Castano C, "Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice", Proc Natl Acad Sci U S A, 115, pp.12158~12163 (2018)
32. Esau C, "miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting", Cell Metab, 3, pp.87~98 (2006)
33. Latorre J, "Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD", Int J Obes(Lond), 41, pp.620~630 (2017)
34. Hsu SH, "Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver", J Clin Invest, 122, pp.2871~2883 (2012)
35. Kim YS, "Liver X receptor alpha activation inhibits autophagy and lipophagy in hepatocytes by dysregulating autophagy-related 4B cysteine peptidase and Rab-8B, reducing mitochondrial fuel oxidation", Hepatology, 73, pp.1307~1326 (2021)
36. Wang M, "Protein misfolding in the endoplasmic reticulum as a conduit to human disease", Nature, 529, pp.326~335 (2016)
37. Lebeaupin C, "Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease", J Hepatol, 69, pp.927~947 (2018)
38. Puri P, "Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease", Gastroenterology, 134, pp.568~576 (2008)
39. Akazawa Y, "Palmitoleate attenuates palmitate-induced Bim and PUMA up-regulation and hepatocyte lipoapoptosis", J Hepatol, 52, pp.586~593 (2010)
40. Volmer R, "Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains", Proc Natl Acad Sci U S A, 110, pp.4628~4633 (2013)
41. Latif MU, "NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression", Gut, 71, pp.2561~2573 (2022)
42. Sunny NE, "Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease", Cell Metab, 14, pp.804~810 (2011)
43. Koliaki C, "Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis", Cell Metab, 21, pp.739~746 (2015)
44. Perez-Carreras M, "Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis", Hepatology, 38, pp.999~1007 (2003)
45. Satapati S, "Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver", J Clin Invest, 125, pp.4447~4462 (2015)
46. Martel C, "Glycogen synthase kinase 3-mediated voltage-dependent anion channel phosphorylation controls outer mitochondrial membrane permeability during lipid accumulation", Hepatology, 57, pp.93~102 (2013)
47. Li Z, "The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity", Hepatology, 47, pp.1495~1503 (2008)
48. Meex RCR, "Mitochondrial dysfunction is a key pathway that links saturated fat intake to the development and progression of NAFLD", Mol Nutr Food Res, 65, pp.e1900942~ (2021)
49. Peng KY, "Mitochondrial dysfunction-related lipid changes occur in nonalcoholic fatty liver disease progression", J Lipid Res, 59, pp.1977~1986 (2018)
50. Chocian G, "High fat diet induces ceramide and sphingomyelin formation in rat’s liver nuclei", Mol Cell Biochem, 340, pp.125~131 (2010)
51. Chavez JA, "A ceramide-centric view of insulin resistance", Cell Metab, 15, pp.585~594 (2012)
52. Arora AS, "Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat", Hepatology, 25, pp.958~963 (1997)
53. Tovoli F, "A relative deficiency of lysosomal acid lypase activity characterizes non-alcoholic fatty liver disease", Int J mol Sci, 18, pp.1134~ (2017)
54. Baratta F, "Reduced lysosomal acid lipase activity in adult patients with non-alcoholic fatty liver disease", EBioMedicine, 2, pp.750~754 (2015)
55. Wang X, "Defective lysosomal clearance of autophagosomes and its clinical implications in nonalcoholic steatohepatitis", FASEB J, 32, pp.37~51 (2018)
56. Feldstein AE, "Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway", Hepatology, 40, pp.185~194 (2004)
57. Hirsova P, "Lipotoxic lethal and sublethal stress signaling in hepatocytes : relevance to NASH pathogenesis", J Lipid Res, 57, pp.1758~1770 (2016)
58. Singh R, "Autophagy regulates lipid metabolism", Nature, 458, pp.1131~1135 (2009)
59. Li S, "Sirtuin 3 acts as a negative regulator of autophagy dictating hepatocyte susceptibility to lipotoxicity", Hepatology, 66, pp.936~952 (2017)
60. Geng Y, "How does hepatic lipid accumulation lead to lipotoxicity in nonalcoholic fatty liver disease?", Hepatol Int, 15, pp.21~35 (2021)
61. Cao L, "Mechanism of hepatocyte apoptosis", J Cell Death, 9, pp.19~29 (2016)
62. Rada P, "Understanding lipotoxicity in NAFLD pathogenesis : is CD36 a key driver?", Cell Death Dis, 11, pp.802~ (2020)
63. Sanyal AJ, "Prospective study of outcomes in adults with nonalcoholic fatty liver disease", N Engl J Med, 385, pp.1559~1569 (2021)
64. Kim Y, "Obesity and weight gain are associated with progression of fibrosis in patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 17, pp.543~550 (2019)
65. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
66. Argo CK, "Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis", J Hepatol, 51, pp.371~379 (2009)
67. Parthasarathy G, "Pathogenesis of nonalcoholic steatohepatitis : an overview", Hepatol Commun, 4, pp.478~492 (2020)
68. Marra F, "Lipotoxicity and the gut-liver axis in NASH pathogenesis", J Hepatol, 68, pp.280~295 (2018)
69. Hirsova P, "Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes", Gastroenterology, 150, pp.956~967 (2016)
70. Canbay A, "Apoptotic body engulfment by a human stellate cell line is profibrogenic", Lab Invest, 83, pp.655~663 (2003)
71. Kwon H, "Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease", Hepatology, 63, pp.1155~1169 (2016)
72. Syn WK, "Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease", Gastroenterology, 137, pp.1478~1488 (2009)
73. Syn WK, "Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis", Hepatology, 53, pp.106~115 (2011)
74. Syn WK, "NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease", Gut, 61, pp.1323~1329 (2012)
75. Shi H, "TLR4links innate immunity and fatty acid-induced insulin resistance", J Clin Invest, 116, pp.3015~3025 (2006)
76. Hetherington AM, "Differential lipotoxic effects of palmitate and oleate in activated human hepatic stellate cells and epithelial hepatoma cells", Cell Physiol Biochem, 39, pp.1648~1662 (2016)
77. Tomita K, "Free cholesterol accumulation in hepatic stellate cells : mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice", Hepatology, 59, pp.154~169 (2014)
78. Paradis V, "High glucose and hyperinsulinemia stimulate connective tissue growth factor expression : a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis", Hepatology, 34, pp.738~744 (2001)
79. Svegliati-Baroni G, "Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells : differential effects on signal transduction pathways", Hepatology, 29, pp.1743~1751 (1999)
80. Cai CX, "Activation of insulin-PI3K", akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis, 2017, pp.62, 968~978
81. Pirazzi C, "PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells", Hum Mol Genet, 23, pp.4077~4085 (2014)
82. Mancina RM, "The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent", Gastroenterology, 150, pp.1219~1230 (2016)
83. Hernandez-Gea V, "Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues", Gastroenterology, 142, pp.938~946 (2012)
84. Thangapandi VR, "Loss of hepatic Mboat7 leads to liver fibrosis", Gut, 70, pp.940~950 (2021)
85. Fondevila MF, "The L-α-lysophosphatidylinositol", G protein-coupled receptor 55 system induces the development of nonalcoholic steatosis and steatohepatitis, 2021, pp.73, 606~624
86. Liu YL, "TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease", Nat Commun, 5, pp.4309~ (2014)
87. Abul-Husn NS, "A protein-truncating HSD17B13 variant and protection from chronic liver disease", N Engl J Med, 378, pp.1096~1106 (2018)
88. Pirola CJ, "Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease", J Lipid Res, 60, pp.176~185 (2019)
89. Luukkonen PK, "Hydroxysteroid 17-β dehydrogenase 13variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease", JCI Insight, 5, pp.e132158~ (2020)
90. Ma Y, "17-beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease", Hepatology, 69, pp.1504~1519 (2019)
91. Zeybel M, "Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease", Clin Epigenetics, 7, pp.25~ (2015)
92. Raman M, "Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 11, pp.868~875 (2013)
93. Mouzaki M, "Intestinal microbiota in patients with nonalcoholic fatty liver disease", Hepatology, 58, pp.120~127 (2013)
94. Mao JW, "Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease", Int J Clin Exp Pathol, 8, pp.3648~3658 (2015)
95. Mencin A, "Toll-like receptors as targets in chronic liver diseases", Gut, 58, pp.704~720 (2009)
96. Henao-Mejia J, "Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity", Nature, 482, pp.179~185 (2012)
97. Farhadi A, "Susceptibility to gut leakiness : a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis", Liver Int, 28, pp.1026~1033 (2008)
98. Yang SQ, "Obesity increases sensitivity to endotoxin liver injury : implications for the pathogenesis of steatohepatitis", Proc Natl Acad Sci U S A, 94, pp.2557~2562 (1997)
99. Rivera CA, "Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis", J Hepatol, 47, pp.571~579 (2007)
100. Miura K, "Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice", Gastroenterology, 139, pp.323~334 (2010)
101. Hsieh YC, "Eritoran attenuates hepatic inflammation and fibrosis in mice with chronic liver injury", Cells, 10, pp.1562~ (2021)
102. Seki E, "TLR4 enhances TGF-beta signaling and hepatic fibrosis", Nat Med, 13, pp.1324~1332 (2007)
103. Mehta G, "Inflammation and portal hypertension-the undiscovered country", J Hepatology, 61, pp.155~163 (2014)
104. Mouries J, "Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development", J Hepatol, 71, pp.1216~1228 (2019)
105. Yuan J, "Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis", J Gastroenterol Hepatol, 29, pp.1292~1298 (2014)
106. Luther J, "Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability", Cell Mol Gastroenterol Hepatol, 1, pp.222~232 (2015)
107. Dumas ME, "Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice", Proc Natl Acad Sci U S A, 103, pp.12511~12516 (2006)
108. Zhang Y, "Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice", Proc Natl Acad Sci U S A, 103, pp.1006~1011 (2006)
109. Holt JA, "Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis", Genes Dev, 17, pp.1581~1591 (2003)
110. Yajima M, "Diversity of the intestinal microbiota differently affects non-neuronal and atropine-sensitive ileal contractile responses to short-chain fatty acids in mice", Biomed Res, 37, pp.319~328 (2016)
111. den Besten G, "Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids", Am J Physiol Gastrointest Liver Physiol, 305, pp.G900~G910 (2013)
112. Samuel BS, "Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41", Proc Natl Acad Sci U S A, 105, pp.16767~16772 (2008)
113. Gao Z, "Butyrate improves insulin sensitivity and increases energy expenditure in mice", Diabetes, 58, pp.1509~1517 (2009)
114. Loomba R, "Gut microbiome-based metagenomic signature for noninvasive detection of advanced fibrosis in human nonalcoholic fatty liver disease", Cell Metab, 25, pp.1054~1062 (2017)
115. Zhu L, "Characterization of gut microbiomes in nonalcoholic steatohepatitis(NASH)patients : a connection between endogenous alcohol and NASH", Hepatology, 57, pp.601~609 (2013)
116. Passos MC, "Regulation of insulin sensitivity by adiponectin and its receptors in response to physical exercise", Horm Metab Res, 46, pp.603~608 (2014)
117. Yamauchi T, "Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase", Nat Med, 8, pp.1288~1295 (2002)
118. Xu A, "The fatderived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice", J Clin Invest, 112, pp.91~100 (2003)
119. Hui JM, "Beyond insulin resistance in NASH : TNF-alpha or adiponectin?", Hepatology, 40, pp.46~54 (2004)
120. Yadav A, "Role of leptin and adiponectin in insulin resistance", Clin Chim Acta, 417, pp.80~84 (2013)
121. Polyzos SA, "Irisin in patients with nonalcoholic fatty liver disease", Metabolism, 63, pp.207~217 (2014)
122. Polyzos SA, "Circulating leptin in non-alcoholic fatty liver disease : a systematic review and meta-analysis", Diabetologia, 59, pp.30~43 (2016)
123. Yang YY, "Hepatic endothelin-1 and endocannabinoids-dependent effects of hyperleptinemia in nonalcoholic steatohepatitis-cirrhotic rats", Hepatology, 55, pp.1540~1550 (2012)
124. Shoelson SE, "Inflammation and insulin resistance", J Clin Invest, 116, pp.1793~1801 (2006)
125. Tilg H, "The role of cytokines in non-alcoholic fatty liver disease", Dig Dis, 28, pp.179~185 (2010)
126. Kakino S, "Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model", Horm Metab Res, 50, pp.80~87 (2018)
127. Han MS, "Regulation of adipose tissue inflammation by interleukin 6", Proc Natl Acad Sci U S A, 117, pp.2751~2760 (2020)
128. Perry RJ, "Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes", Cell, 160, pp.745~758 (2015)
129. Goh GB, "Renin-angiotensin system and fibrosis in nonalcoholic fatty liver disease", Liver Int, 35, pp.979~985 (2015)
130. Zhang X, "Angiotensin-converting enzyme inhibitors prevent liverrelated events in nonalcoholic fatty liver disease", Hepatology, 76, pp.469~482 (2021)
131. Wei Y, "Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2)rats", J Hepatol, 49, pp.417~428 (2008)
132. Takahashi N, "Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin", Cell Metab, 6, pp.506~512 (2007)
133. Lee KC, "Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet", PLoS One, 8, pp.e77817~ (2013)
134. Lee KC, "Aliskiren reduces hepatic steatosis and epididymal fat mass and increases skeletal muscle insulin sensitivity in high-fat diet-fed mice", Sci Rep, 6, pp.18899~ (2016)
135. Nguyen G, "Pivotal role of the renin", prorenin receptor in angiotensin II production and cellular responses to renin, 2002, pp.109, 1417~1427
136. Oliver JA, "Receptor-mediated actions of renin and prorenin", Kidney Int, 69, pp.13~15 (2006)
137. Huang Y, "Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptormediated, angiotensin II-independent mechanisms", Kidney Int, 69, pp.105~113 (2006)
138. Hsieh YC, "(Pro)renin receptor knockdown attenuates liver fibrosis through inactivation of ERK", TGF-β1, Cell Mol Gastroenterol Hepatol, pp.2021, 12[DOI]
139. Ren L, "(Pro)renin receptor inhibition reprograms hepatic lipid metabolism and protects mice from diet-induced obesity and hepatosteatosis", Circ Res, 122, pp.730~741 (2018)
140. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
141. Anstee QM, "From NASH to HCC : current concepts and future challenges", Nat Rev Gastroenterol Hepatol, 16, pp.411~428 (2019)
142. Schwabe RF, "Gut microbiome in HCC-mechanisms, diagnosis and therapy", J Hepatol, 72, pp.230~238 (2020)
143. Park EJ, "Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression", Cell, 140, pp.197~208 (2010)
144. Nakagawa H, "ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development", Cancer Cell, 26, pp.331~343 (2014)
145. Tanaka S, "Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma", J Gastroenterol, 48, pp.1249~1258 (2013)
146. Gomes AL, "Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma", Cancer Cell, 30, pp.161~175 (2016)
147. Ma C, "NAFLD causes selective CD4(+)T lymphocyte loss and promotes hepatocarcinogenesis", Nature, 531, pp.253~257 (2016)
148. Leslie J, "CXCR2 inhibition enables NASH-HCC Immunotherapy", Gut, 71, pp.2093~2106 (2022)
149. Ye J, "JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity", Cancer Res, 77, pp.5287~5300 (2017)
150. Guri Y, "mTORC2 promotes tumorigenesis via lipid synthesis", Cancer Cell, 32, pp.807~823 (2017)
151. Fujiwara N, "CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity", Gut, 67, pp.1493~1504 (2018)
152. Wu H, "MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway", Gut, 65, pp.1850~1860 (2016)
153. Dapito DH, "Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4", Cancer Cell, 21, pp.504~516 (2012)
154. Liu YL, "Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma", J Hepatol, 61, pp.75~81 (2014)
155. Haufe S, "Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects", Hepatology, 53, pp.1504~1514 (2011)
156. European Association for the Study of the Liver, "EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
157. Eslam M, "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease", Hepatol Int, 14, pp.889~919 (2020)
158. Younossi ZM, "AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease : expert review", Gastroenterology, 160, pp.912~918 (2021)
159. Wong VW, "Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease", J Hepatol, 69, pp.1349~1356 (2018)
160. Wong VW, "Community-based lifestyle modification programme for non-alcoholic fatty liver disease : a randomized controlled trial", J Hepatol, 59, pp.536~542 (2013)
161. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378 (2015)
162. Storlien LH, "Fish oil prevents insulin resistance induced by high-fat feeding in rats", Science, 237, pp.885~888 (1987)
163. Sekiya M, "Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression", Hepatology, 38, pp.1529~1539 (2003)
164. Levy JR, "Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats", Hepatology, 39, pp.608~616 (2004)
165. Parker HM, "Omega-3 supplementation and non-alcoholic fatty liver disease : a systematic review and meta-analysis", J Hepatol, 56, pp.944~951 (2012)
166. Molloy JW, "Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis", Hepatology, 55, pp.429~436 (2012)
167. Wijarnpreecha K, "Coffee consumption and risk of nonalcoholic fatty liver disease : a systematic review and meta-analysis", Eur J Gastroenterol Hepatol, 29, pp.e8~e12 (2017)
168. Hashida R, "Aerobic vs. resistance exercise in non-alcoholic fatty liver disease : a systematic review", J Hepatol, 66, pp.142~152 (2017)
169. Sullivan S, "Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease", Hepatology, 55, pp.1738~1745 (2012)
170. Kistler KD, "Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease", Am J Gastroenterol, 106, pp.460~468 (2011)
171. Puzziferri N, "Long-term follow-up after bariatric surgery : a systematic review", JAMA, 312, pp.934~942 (2014)
172. O’Brien PE, "Long-term outcomes after bariatric surgery : a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding", Obes Surg, 29, pp.3~14 (2019)
173. Lee Y, "Complete resolution of nonalcoholic fatty liver disease after bariatric surgery : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 17, pp.1040~1060 (2019)
174. Zhou H, "Bariatric surgery improves nonalcoholic fatty liver disease : systematic review and meta-analysis", Obes Surg, 32, pp.1872~1883 (2022)
175. Wirth KM, "Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis : a retrospective cohort analysis", Ann Surg, 272, pp.32~39 (2020)
176. Rustgi VK, "Bariatric surgery reduces cancer risk in adults with nonalcoholic fatty liver disease and severe obesity", Gastroenterology, 161, pp.171~184 (2021)
177. Aminian A, "Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis", JAMA, 326, pp.2031~2042 (2021)
178. Chandan S, "Efficacy and safety of intragastric balloon(IGB)in non-alcoholic fatty liver disease(NAFLD) : a comprehensive review and meta-analysis", Obes Surg, 31, pp.1271~1279 (2021)
179. Bazerbachi F, "Intragastric balloon placement induces significant metabolic and histologic improvement in patients with nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 19, pp.146~154 (2021)
180. Hajifathalian K, "Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty", Gastrointest Endosc, 93, pp.1110~1118 (2021)
181. van Baar ACG, "Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes : 6-month multicentre results", JHEP Rep, 1, pp.429~437 (2019)
182. Karlas T, "Endoscopic bariatric treatment with duodenal-jejunal bypass liner improves non-invasive markers of non-alcoholic Steatohepatitis", Obes Surg, 32, pp.2495~2503 (2022)
183. Zhou D, "Total fecal microbiota transplantation alleviates high-fat dietinduced steatohepatitis in mice via beneficial regulation of gut microbiota", Sci Rep, 7, pp.1529~ (2017)
184. Mocanu V, "Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome : a randomized double-blind, placebo-controlled phase 2 trial", Nat Med, 27, pp.1272~1279 (2021)
185. Witjes JJ, "Donor fecal microbiota transplantation alters gut microbiota and metabolites in obese individuals with steatohepatitis", Hepatol Commun, 4, pp.1578~1590 (2020)
186. Craven L, "Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability : a randomized control trial", Am J Gastroenterol, 115, pp.1055~1065 (2020)
187. Sumida Y, "Current and future pharmacological therapies for NAFLD", NASH, 2018, pp.53, 362~376
188. Belfort R, "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N Engl J Med, 355, pp.2297~2307 (2006)
189. Aithal GP, "Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis", Gastroenterology, 135, pp.1176~1184 (2008)
190. Huang JF, "Firstin-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients", Hepatol Int, 15, pp.1136~1147 (2021)
191. Harrison SA, "RESOLVE-IT phase 3 trial of elafibranor in NASH : final results of the week 72 interim surrogate efficacy analysis;2020 Nov 13-Nov 16", AASLD The Liver Meeting (2020)
192. Nakajima A, "Randomised clinical trial : pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator(SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 54, pp.1263~1277 (2021)
193. Francque SM, "A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH", N Engl J Med, 385, pp.1547~1558 (2021)
194. Armstrong MJ, "Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis(LEAN) : a multicentre, doubleblind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
195. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
196. Wei Q, "Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials", Front Endocrinol(Lausanne), 12, pp.635556~ (2021)
197. Harrison SA, "Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis", Gastroenterology, 160, pp.219~231 (2021)
198. Sanyal A, "Pegbelfermin(BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis : a randomised, double-blind, placebo-controlled, phase 2a trial", Lancet, 392, pp.2705~2717 (2019)
199. Harrison SA, "Efruxifermin in non-alcoholic steatohepatitis : a randomized, double-blind, placebo-controlled, phase 2a trial", Nat Med, 27, pp.1262~1271 (2021)
200. Calle RA, "ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease : two parallel, placebo-controlled, randomized phase 2a trials", Nat Med, 27, pp.1836~1848 (2021)
201. Ratziu V, "Aramchol in patients with nonalcoholic steatohepatitis : a randomized, double-blind, placebo-controlled phase 2b trial", Nat Med, 27, pp.1825~1835 (2021)
202. Harrison SA, "Resmetirom(MGL-3196)for the treatment of non-alcoholic steatohepatitis : a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial", Lancet, 394, pp.2012~2024 (2019)
203. Vilar-Gomez E, "Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis", Hepatology, 71, pp.495~509 (2020)
204. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
205. Harrison SA, "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH : results from randomized phase III STELLAR trials", J Hepatol, 73, pp.26~39 (2020)
206. Harrison SA, "A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed nonalcoholic steatohepatitis and type 2 diabetes", Nat Commun, 12, pp.5503~ (2021)
207. Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis(FLINT) : a multicentre, randomised, placebocontrolled trial", Lancet, 385, pp.956~965 (2015)
208. Mudaliar S, "Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease", Gastroenterology, 145, pp.574~582 (2013)
209. Younossi ZM, "Obeticholic acid for the treatment of nonalcoholic steatohepatitis : interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
210. Harrison SA, "A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis", J Hepatol, 72, pp.816~827 (2020)
211. Garcia-Tsao G, "Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension", J Hepatol, 72, pp.885~895 (2020)
212. Friedman SL, "A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis", Hepatology, 67, pp.1754~1767 (2018)
213. Ratziu V, "Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis : final analysis of the phase 2b CENTAUR study", Hepatology, 72, pp.892~905 (2020)
214. Chalasani N, "Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension", Gastroenterology, 158, pp.1334~1345 (2020)
215. Dufour JF, "Combination therapy for nonalcoholic steatohepatitis : rationale, opportunities and challenges", Gut, 69, pp.1877~1884 (2020)
216. Loomba R, "Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH", Hepatology, 73, pp.625~643 (2021)
217. Alkhouri N, "Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis : a randomised, open-label phase II trial", J Hepatol, 77, pp.607~618 (2022)

관련 논문AI추천